Researchers evaluated the 5-year effectiveness and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) for patients with primary and secondary glaucoma. The procedure aims to reduce intraocular pressure (IOP) while minimizing damage to ocular structures. The investigators found that MP-TSCPC is a safe and effective treatment for lowering IOP and decreasing the number of IOP-lowering medications, especially after failed incisional glaucoma surgery or for patients who are at high risk for incisional surgery.

Source: Ophthalmology and Therapy